IGLL5 and plasma cell myeloma: Previous studies have found that IGLL5, a other biomarker that is more specifically expressed under dominant disease conditions, has the potential to serve as an emerging biomarker for targeted therapy (65).Therefore, this subgroup, characterized by the expression of IGLL5, held significant relevance in understanding the mechanisms underlying the progression of multiple myeloma.